Patient journey in gastroesophageal reflux disease : real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists
© The Author(s), 2024..
Background: Gastroesophageal reflux disease (GERD) is a challenging condition that involves different physicians, such as general practitioners (GPs), gastroenterologists, and ears, nose and throat (ENT) specialists. A common approach consists of proton-pump inhibitors (PPIs) administration. Adjunctive pharmacological treatment may have a role in the management of non-responders to PPIs.
Objectives: We aimed to survey GPs and different medical specialists to investigate the medical approaches to patients reporting GERD symptoms. In addition, we examined the use of adjunctive pharmacological treatments in patients with GERD symptoms who do not respond to PPIs.
Design: Retrospective observational study.
Methods: A survey was conducted among a large sample of gastroenterologists, GPs, and ENT specialists. Symptoms were divided into typical and extraesophageal, and their severity and impact on quality of life were explored with the GERD Impact Scale and with Reflux Symptom Index (RSI). All therapies administered usually for GERD were investigated.
Results: A total of 6211 patients were analyzed in this survey. Patients with typical symptoms were 53.5%, while those with extraesophageal symptoms were 46.5%. The latter were more frequently reported by ENT patients (53.6%, p < 0.0001). The GSI was higher in patients followed by gastroenterologists (9 points) and GPs (9 points) than ENT specialists (8 points), but the RSI was higher in the ENT group (14.3 ± 6.93) than in GPs and gastroenterologist groups (10.36 ± 6.36 and 10.81 ± 7.30, p < 0.0001). Chest pain had the highest negative impact on quality of life (p < 0.0001). Of the 3025 patients who used PPIs, non-responders showed a lower GSI when treated with a combination of adjunctive pharmacological treatments and bioadhesive compounds, than with single-component drugs.
Conclusion: Patients with GERD referred to a gastroenterologist had more severe disease and poorer quality of life. The combination of adjunctive pharmacological treatments and bioadhesive compounds seems to be effective in the management of PPI refractory patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Therapeutic advances in gastroenterology - 17(2024) vom: 30., Seite 17562848241239590 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pasta, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acid suppressive therapy |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17562848241239590 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37014368X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37014368X | ||
| 003 | DE-627 | ||
| 005 | 20240327000225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240326s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17562848241239590 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM37014368X | ||
| 035 | |a (NLM)38524789 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pasta, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient journey in gastroesophageal reflux disease |b real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2024. | ||
| 520 | |a Background: Gastroesophageal reflux disease (GERD) is a challenging condition that involves different physicians, such as general practitioners (GPs), gastroenterologists, and ears, nose and throat (ENT) specialists. A common approach consists of proton-pump inhibitors (PPIs) administration. Adjunctive pharmacological treatment may have a role in the management of non-responders to PPIs | ||
| 520 | |a Objectives: We aimed to survey GPs and different medical specialists to investigate the medical approaches to patients reporting GERD symptoms. In addition, we examined the use of adjunctive pharmacological treatments in patients with GERD symptoms who do not respond to PPIs | ||
| 520 | |a Design: Retrospective observational study | ||
| 520 | |a Methods: A survey was conducted among a large sample of gastroenterologists, GPs, and ENT specialists. Symptoms were divided into typical and extraesophageal, and their severity and impact on quality of life were explored with the GERD Impact Scale and with Reflux Symptom Index (RSI). All therapies administered usually for GERD were investigated | ||
| 520 | |a Results: A total of 6211 patients were analyzed in this survey. Patients with typical symptoms were 53.5%, while those with extraesophageal symptoms were 46.5%. The latter were more frequently reported by ENT patients (53.6%, p < 0.0001). The GSI was higher in patients followed by gastroenterologists (9 points) and GPs (9 points) than ENT specialists (8 points), but the RSI was higher in the ENT group (14.3 ± 6.93) than in GPs and gastroenterologist groups (10.36 ± 6.36 and 10.81 ± 7.30, p < 0.0001). Chest pain had the highest negative impact on quality of life (p < 0.0001). Of the 3025 patients who used PPIs, non-responders showed a lower GSI when treated with a combination of adjunctive pharmacological treatments and bioadhesive compounds, than with single-component drugs | ||
| 520 | |a Conclusion: Patients with GERD referred to a gastroenterologist had more severe disease and poorer quality of life. The combination of adjunctive pharmacological treatments and bioadhesive compounds seems to be effective in the management of PPI refractory patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GERD | |
| 650 | 4 | |a acid suppressive therapy | |
| 650 | 4 | |a alginate | |
| 650 | 4 | |a atypical symptoms | |
| 650 | 4 | |a mucosal protectants | |
| 650 | 4 | |a reflux disease | |
| 700 | 1 | |a Pelizzaro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Marabotto, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Formisano, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Djahandideh Sheijani, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Brandimarte, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Manes, Giampiero |e verfasserin |4 aut | |
| 700 | 1 | |a Gravina, Antonietta Gerarda |e verfasserin |4 aut | |
| 700 | 1 | |a Savarino, Edoardo Vincenzo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in gastroenterology |d 2008 |g 17(2024) vom: 30., Seite 17562848241239590 |w (DE-627)NLM193041979 |x 1756-283X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:30 |g pages:17562848241239590 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17562848241239590 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 30 |h 17562848241239590 | ||